Tilpazan 284mg Injection 1.5 ml is a medicine containing Inclisiran as an active ingredient, which belongs to the class of medications called proprotein convertase subtilisin kexin type-9 [PCSK-9]. It is the first in class and the only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. It is used to lower the level of low-density lipoprotein. It is prescribed as a complement to statin medication and diet in the management of patients with primary high cholesterol levels. 

It is not recommended to use this medication if you are allergic to the active compound Tilpazan Injection or its components. It is not recommended to use during pregnancy and breastfeeding; it is advised to consult your physician regarding further queries. It is not recommended for children and adolescents under the age of 18. You should be taking a statin and following a diet to reduce your cholesterol before beginning this therapy. For the duration that you are receiving Tilpazan 284mg Injection 1.5 ml, you should continue taking the statin and adhering to this cholesterol-lowering diet. Do not stop taking this medicine without consulting your doctor. Talk to your doctor if you have kidney disorders, breathing problems, liver disorders, heart problems, or intolerance to sugars before taking this medicine. Inform your physician or pharmacist of any additional medications you are taking, have recently taken, or may take, including over-the-counter medications and herbal remedies.

Combination with other statin therapy and diet for treating primary hyperlipidemia (heterozygous familial hypercholesterolemia).

Tilpazan 284mg Injection 1.5 ml is a small interfering RNA (siRNA) molecule that interferes with the production of PCSK9 protein in the liver. By inhibiting PCSK9 synthesis, Tilpazan 284mg Injection 1.5 ml increases the number of LDL receptors on liver cells, promoting the clearance of LDL cholesterol from the blood. This mechanism ultimately leads to lower LDL cholesterol levels in the bloodstream, helping to reduce the risk of cardiovascular events such as heart attack and stroke.

Tilpazan 284mg Injection 1.5 ml will be administered to you by a healthcare professional in a hospital setting. It is usually administered as a subcutaneous injection into the abdomen, upper arm, or thigh. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors. The second dose is given after 3 months and the subsequent dose every 6 months.

Common:

Injection site reactions like redness, rash and pain

Arthralgia

Bronchitis

Fever

Chills

Headache

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Tilpazan 284mg Injection 1.5 ml and reduce effectiveness by causing undesirable side effects.

• Tilpazan 284mg Injection 1.5 ml should be stored at room temperature, between 20°C to 25°C (68°F to 77°F).
• Protected from light.
• Keep it in its original packaging until it is ready to be used.
• Keep out of the reach of children and pets.
• Should be disposed of properly.

It is advised to adopt heart-healthy lifestyle practices, such as eating a balanced diet low in saturated and trans fats, exercising frequently, keeping a healthy weight, and quitting smoking, in addition to taking Tilpazan 284mg Injection 1.5 ml. It is advised not to stop your regular statin medications and follow a proper diet since Tilpazan 284mg Injection 1.5 ml is only effective along with these two therapies. It is not recommended to discontinue the drug without the advice of a healthcare professional even if your symptoms improve. Follow your doctor's advice and routinely check your cholesterol levels. This facilitates monitoring Tilpazan 284mg Injection 1.5 ml's efficacy and enables prompt modification of your treatment regimen, if necessary. If a dose is missed for more than three months, a new dosing regimen needs to be initiated.